Stock Yards Bank & Trust Co. Has $3.72 Million Position in CVS Health Co. (NYSE:CVS)

Stock Yards Bank & Trust Co. boosted its position in shares of CVS Health Co. (NYSE:CVS) by 6.4% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 47,127 shares of the pharmacy operator’s stock after purchasing an additional 2,841 shares during the quarter. Stock Yards Bank & Trust Co.’s holdings in CVS Health were worth $3,721,000 as of its most recent SEC filing.

Other institutional investors have also recently bought and sold shares of the company. Atticus Wealth Management LLC boosted its holdings in shares of CVS Health by 149.0% in the fourth quarter. Atticus Wealth Management LLC now owns 366 shares of the pharmacy operator’s stock valued at $29,000 after buying an additional 219 shares during the period. Cornerstone Planning Group LLC boosted its holdings in shares of CVS Health by 111.5% in the third quarter. Cornerstone Planning Group LLC now owns 461 shares of the pharmacy operator’s stock valued at $32,000 after buying an additional 243 shares during the period. ZRC Wealth Management LLC boosted its holdings in shares of CVS Health by 400.0% in the fourth quarter. ZRC Wealth Management LLC now owns 500 shares of the pharmacy operator’s stock valued at $39,000 after buying an additional 400 shares during the period. Coston McIsaac & Partners boosted its holdings in shares of CVS Health by 42.6% in the fourth quarter. Coston McIsaac & Partners now owns 539 shares of the pharmacy operator’s stock valued at $42,000 after buying an additional 161 shares during the period. Finally, Tennessee Valley Asset Management Partners acquired a new position in shares of CVS Health in the fourth quarter valued at approximately $50,000. Institutional investors and hedge funds own 80.66% of the company’s stock.

CVS Health Price Performance

Shares of CVS opened at $69.61 on Tuesday. The firm has a market capitalization of $87.74 billion, a PE ratio of 10.78, a PEG ratio of 0.92 and a beta of 0.52. The company’s 50-day moving average is $75.13 and its 200-day moving average is $73.77. CVS Health Co. has a fifty-two week low of $64.41 and a fifty-two week high of $83.25. The company has a debt-to-equity ratio of 0.77, a current ratio of 0.86 and a quick ratio of 0.63.

CVS Health (NYSE:CVS) last issued its quarterly earnings data on Wednesday, February 7th. The pharmacy operator reported $2.12 earnings per share for the quarter, beating the consensus estimate of $2.01 by $0.11. The company had revenue of $93.81 billion for the quarter, compared to analyst estimates of $90.58 billion. CVS Health had a net margin of 2.33% and a return on equity of 15.25%. The company’s revenue was up 11.9% on a year-over-year basis. During the same period in the prior year, the firm earned $1.99 earnings per share. Equities analysts forecast that CVS Health Co. will post 8.32 EPS for the current year.

CVS Health Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, May 1st. Stockholders of record on Monday, April 22nd will be given a $0.665 dividend. This represents a $2.66 annualized dividend and a dividend yield of 3.82%. The ex-dividend date of this dividend is Friday, April 19th. CVS Health’s payout ratio is presently 41.18%.

Insider Activity

In related news, EVP Prem S. Shah sold 29,473 shares of the company’s stock in a transaction dated Friday, February 16th. The shares were sold at an average price of $76.95, for a total value of $2,267,947.35. Following the transaction, the executive vice president now directly owns 39,765 shares in the company, valued at $3,059,916.75. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 0.24% of the company’s stock.

Wall Street Analysts Forecast Growth

CVS has been the subject of several research analyst reports. SVB Leerink initiated coverage on shares of CVS Health in a report on Monday, February 26th. They issued an “outperform” rating and a $88.00 price target for the company. Barclays began coverage on shares of CVS Health in a research report on Wednesday, March 6th. They issued an “equal weight” rating and a $78.00 price objective on the stock. StockNews.com lowered shares of CVS Health from a “buy” rating to a “hold” rating in a research report on Thursday, February 15th. Cantor Fitzgerald reissued an “overweight” rating and issued a $87.00 price objective on shares of CVS Health in a research report on Wednesday, April 10th. Finally, Royal Bank of Canada cut their price objective on shares of CVS Health from $86.00 to $84.00 and set an “outperform” rating on the stock in a research report on Thursday, February 8th. Four analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. According to MarketBeat.com, CVS Health currently has an average rating of “Moderate Buy” and a consensus price target of $89.44.

About CVS Health

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.